Citeline's Chinatrove® Provides Pharma Industry with Transparency into the Chinese Clinical Trial Market
New Service Helps Prequalify Chinese Hospitals for Clinical Trials
NEW YORK, Jan. 6, 2015 /PRNewswire/ -- Citeline®, an Informa business unit, and the pharmaceutical industry's leading research authority on clinical trials, today announced the official release of Chinatrove, the newest addition to its suite of pharma R&D intelligence services.
Chinatrove is designed to help pharmaceutical companies and CROs streamline their identification of potential sites from among CFDA-certified hospitals. These are the only sites sanctioned for running local clinical trials: a government requirement for anyone aiming to bring a new drug to market in China.
www.citeline.com/products/chinatrove
Supporting Well-Informed Decisions
Assuming CFDA approved hospitals have the specific equipment and infrastructure needed for a trial can be a costly oversight. Chinatrove will help companies generate better site target lists by providing key site prequalification information, including key clinical department heads' contact information.
"Well regarded industry experts have shared with Citeline that trial sites in China have failed due to lack of critical medical or laboratory equipment." said Christine Blazynski, Ph.D., Senior Vice President, New Product Development. "We sought a solution to help minimize these failures and developed Chinatrove. And, in building this new product, we feel we've added transparency to the clinical trial space around the world's largest population and market."
Shortening the Site Selection Cycle
Knowing which hospitals have the right disease certifications, the appropriate departments with adequate numbers of specialists, hospital level and grade, bed count, outpatient turnover/day, and required diagnostic, treatment and laboratory equipment will facilitate decision-making by both the pharma companies and CROs seeking to run trials in China.
"The numbers of public hospitals approved to run clinical trials is growing." commented Cydney Brooks, Ph.D., Senior Director, Product Management & Strategy. "The breadth of diseases receiving CFDA approval is also increasing, as well as penetration beyond the very large city hospitals into smaller hospitals and cities – all of which create potential opportunities for selecting sites."
About Citeline
Citeline delivers the pharmaceutical industry's most robust, reliable, and relevant R&D intelligence—all with direct, unlimited analyst support. Citeline's suite of fully integrated solutions features an unmatched data collection of global clinical trials, drug development pipelines, investigators and site profiles. Citeline data is drawn from over 30,000 unique sources and updated in real-time by the industry's largest team of expert analysts and editors. www.citeline.com
Contact for Further Information
Julie McKenna
Manager, Product Management & Market Strategy
Citeline Inc.
52 Vanderbilt Ave
11th Floor
New York, NY 10017
617-415-1981
[email protected]
Logo - http://photos.prnewswire.com/prnh/20120917/NE75453LOGO
SOURCE Citeline
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article